On the Safety of COVID-19 Vaccine Prophylaxis in Rheumato- logical Patients: Results and Prospects

On the Safety of COVID-19 Vaccine Prophylaxis in Rheumato- logical Patients: Results and Prospects

The coronavirus disease pandemic 2019 (novel coronavirus disease, COVID-19) has attracted the attention of the medical community to new clinical and fundamental problems of human disease immunopathology. Despite the lifting of the international emergency regime and the announcement of the end of the...

Full description

Saved in:

Bibliographic Details
Main Authors:	B. S. Belov, N. V. Muravyeva, O. B. Perepechaeva
Format:	Article
Language:	Russian
Published:	LLC "Publishing House OKI" 2025-06-01
Series:	Антибиотики и Химиотерапия
Subjects:	covid-19 rheumatic diseases vaccination adverse events safety monoclonal antibodies pre-exposure prophylaxis
Online Access:	https://www.antibiotics-chemotherapy.ru/jour/article/view/1228
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Safety of COVID-19 vaccines in patients with immunoinflammatory rheumatic diseases (preliminary data)
by: A. N. Kulikov, et al.
Published: (2022-02-01)

An open-label phase II trial of sotrovimab (VIR-7831) prophylaxis against COVID-19 infection in immunocompromised individuals with impaired SARS-CoV-2 humoral immunity
by: Isabel H. Gonzalez-Bocco, et al.
Published: (2025-10-01)

Development of broad‐spectrum human monoclonal antibodies for rabies post‐exposure prophylaxis
by: Paola De Benedictis, et al.
Published: (2016-03-01)

Vaccination against SARS-CoV-2 in rheumatic diseases: Safety issues
by: B. S. Belov, et al.
Published: (2022-03-01)

Safety of Gam-COVID-Vac (Sputnik V) Combined Vector Vaccine in Patients With Immunoinflammatory Rheumatic Diseases: Preliminary Data
by: A. N. KULIKOV, et al.
Published: (2022-11-01)

Research trends in anti-rabies virus monoclonal antibody: A bibliometric analysis
by: Cheng Liu, et al.
Published: (2025-12-01)

Efficacy, Immunogenicity, and Safety of the Combined Vector Vaccine Gam-COVID-Vac in Patients with Rheumatic Diseases
by: A. N. Kulikov, et al.
Published: (2024-11-01)

The use of the combined vector vaccine GamCOVID-Vac (Sputnik V) in patients with immuno-inflammatory rheumatic diseases: safety issues-news
by: A. N. Kulikov, et al.
Published: (2023-06-01)

Understanding the journey towards rabies vaccination for travellers: Results of a cross-sectional survey with patients and providers in the US, Germany, Sweden, and Switzerland
by: Jennifer Cummins, et al.
Published: (2024-11-01)

Efficacy and safety of the Gam-COVID-Vac in patients with immunoinflammatory rheumatic diseases: preliminary data of prospective study
by: A. N. Kulikov, et al.
Published: (2023-12-01)

Perceptions about HIV pre-exposure prophylaxis among healthcare professionals in Spain (PERPPRES Study)
by: Javier Sánchez-Rubio Ferrández, et al.
Published: (2016-07-01)

Consultations for HIV post-exposure prophylaxis before and after health insurance coverage of pre-exposure prophylaxis to a university-based emergency department in Germany
by: Lennert Böhm, et al.
Published: (2023-12-01)

Vaccination against yellow fever in rheumatic diseases
by: B. S. Belov, et al.
Published: (2019-10-01)

Adverse effects of monoclonal antibodies in the treatment of moderate-to-severe asthma: a narrative review
by: Izabela Orzołek, et al.
Published: (2024-11-01)

GOLIMUMAB SAFETY ACCORDING TO CLINICAL FINDINGS
by: G. V. Lukina, et al.
Published: (2015-04-01)

Emergent informal use of doxycycline post- and pre-exposure prophylaxis among men who have sex with men and transgender and gender diverse people, the Netherlands, 2024
by: Vita W Jongen
Published: (2025-07-01)

A theoretical model influencing the use of pre-exposure prophylaxis in MSM population: a qualitative study from Beijing
by: Yongbing Sun, et al.
Published: (2025-06-01)

Experiences of HIV pre-exposure prophylaxis users during the flood in Porto Alegre
by: Deise Taurino Ramos, et al.
Published: (2025-08-01)

Post-exposure prophylaxis with SA58 (anti-SARS-COV-2 monoclonal antibody) nasal spray for the prevention of symptomatic COVID-19 in healthy adult workers: a randomized, single-blind, placebo-controlled clinical study*
by: Rui Song, et al.
Published: (2023-12-01)

Correlations between Humoral Immunity, Vaccination Period and Demographic Characteristics of First Immunized Smallpox Vaccine Recipients
by: O. S. Ermilova, et al.
Published: (2020-03-01)

Retention of clients in HIV oral pre-exposure prophylaxis care in Engela, Namibia
by: Kristiana Kosmas, et al.
Published: (2025-06-01)

Vaccinoprophylaxis of infections and activity of immuno-inflammatory rheumatic diseases: pro et contra
by: B. S. Belov, et al.
Published: (2024-04-01)

Factors influencing adverse events following COVID-19 vaccination
by: Paola Villanueva, et al.
Published: (2024-12-01)

Evaluating adherence in an active-controlled HIV pre-exposure prophylaxis trial (PrEPVacc) to inform the estimation of HIV incidence in a counterfactual placebo arm
by: Sheila Kansiime, et al.
Published: (2025-12-01)

Modelling the impact of initiation delay, duration and prior PrEP on the efficacy of post‐exposure prophylaxis containing a tenofovir/emtricitabine backbone
by: Lanxin Zhang, et al.
Published: (2025-06-01)

Epidemiological Analysis of the Effectiveness of Rabies Post-Exposure Prophylaxis in the Russian Federation (2001–2018)
by: D. N. Nashatyreva, et al.
Published: (2021-09-01)

A modified pharmacy provider‐led delivery model of oral HIV pre‐ and post‐exposure prophylaxis in Kenya: a pilot study extension
by: Stephanie D. Roche, et al.
Published: (2025-06-01)

POST-EXPOSURE PROPHYLAXIS OF VARICELLA IN ORDER TO STOP INFECTION OUTBREAKS IN KRASNOYARSK CHILDREN ORGANIZED GROUPS
by: N. V. Bakhareva, et al.
Published: (2012-03-01)

The science at HIVR4P 2024: The era of choice in biomedical HIV prevention
by: Beatriz Grinsztejn, et al.
Published: (2025-07-01)

Immunogenicity and safety of tixagevimab-cilgavimab for COVID-19 pre-exposure prophylaxis in immunocompromised 20 to <40 kg children and adolescents: A pilot, prospective, open-labeled study
by: Jassada Buaboonnam, et al.
Published: (2024-12-01)

Modern Ideas about Vaccination of Patients with Rheumatic Diseases: the View of ACR Experts
by: B. S. Belov, et al.
Published: (2023-10-01)

Factors associated with interrupted pre-exposure prophylaxis (PrEP) in a Brazilian cohort: a brief communication
by: Patricia Matias Pinheiro, et al.
Published: (2025-08-01)

Vaccine Prophylaxis of Herpes Zoster In Rheumatic Diseases: Paradigm Revision and New Opportunities
by: G. I. Gridneva, et al.
Published: (2022-08-01)

Limited awareness and use of HIV post‐exposure prophylaxis among people vulnerable to HIV acquisition in Western Kenya: a cross‐sectional analysis
by: Glenna Schluck, et al.
Published: (2025-06-01)

Online delivery of oral HIV pre‐ and post‐exposure prophylaxis: findings from the ePrEP Kenya pilot
by: Catherine Kiptinness, et al.
Published: (2025-06-01)

Safety of COVID-19 vaccines
by: B. K. Romanov
Published: (2022-12-01)

The efficacy and safety of naproxen in acute rheumatic fever: The comparative results of 11-year experience with acetylsalicylic acid and naproxen
by: İbrahim İlker Çetin, et al.
Published: (2016-10-01)

Integrated HIV and STIs response: Trends in syphilis incidence and uptake of oral pre-exposure prophylaxis in Zambia
by: Kutha Banda, et al.
Published: (2025-07-01)

One-step ahead: evaluating the efficacy of single-visit rabies pre-exposure prophylaxis against conventional multi-visit protocol: a randomized non-inferiority clinical trial
by: Aman Dev Singh, et al.
Published: (2025-08-01)

A real-world safety surveillance study of aducanumab through the FDA adverse event reporting system
by: Jingjing Huang, et al.
Published: (2025-03-01)